Dana-Farber Cancer Institute Announces Groundbreaking Research Collaboration to Improve Quality of Life for Metastatic Inflammatory Breast Cancer Patients
In a significant move to advance the treatment of patients with inflammatory breast cancer (IBC), Dana-Farber Cancer Institute, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James), and the Inflammatory Breast Cancer Research Foundation today announced a collaborative research initiative uniting two comprehensive IBC clinics.
The collaborative research project will include patients from both Dana-Farber and the OSUCCC – James, to focus on identifying critical information to address the unique challenges posed by metastatic IBC. By combining the clinical and research capabilities of institutes with the patient-centric funding focus of IBCRF, this initiative will drive progress in improving the quality of life for patients affected by this devastating condition.
"This collaboration represents a remarkable opportunity to make a difference in the lives of patients with metastatic IBC," said Dr. Faina Nakhlis of Dana-Farber. "By bringing together bright minds and the most advanced resources, we are confident that this research will yield insights that will empower patients to make informed decisions about their treatment and ultimately improve their quality of life."
